Viromed Medical AGXTER:VME -2.04%15 EBITDA Margin % is -5.21% as of Dec. 2025. GuruFocus rates XTER:VME with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Viromed Medical AG ranks worse than 68.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Viromed Medical AG's EBITDA for the
six
months ended in Dec. 2025 was €-0.27 Mil. Viromed Medical AG's Revenue for the
six
months ended in Dec. 2025 was €5.09 Mil. Therefore, Viromed Medical AG's EBITDA margin for the quarter that ended in Dec. 2025 was -5.21%.
Viromed Medical AG (XTER:VME) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Viromed Medical AG EBITDA Margin % Related Terms
Viromed Medical AG EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Viromed Medical AG's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:VME vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Viromed Medical AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viromed Medical AG EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Viromed Medical AG's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viromed Medical AG (XTER:VME) has a EBITDA Margin % of -5.21% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viromed Medical AG and its competitors. According to the industry distribution chart, Viromed Medical AG ranks #557 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 68.3%.
Is Viromed Medical AG's EBITDA Margin % too high?
Viromed Medical AG's current EBITDA Margin % is -5.21%. Based on the distribution chart, Viromed Medical AG ranks #557 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Viromed Medical AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Viromed Medical AG ranks #557 out of 816 companies for EBITDA Margin %. This places Viromed Medical AG in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Viromed Medical AG and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viromed Medical AG's current EBITDA Margin % is -5.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (XTER:VME) has a current EBITDA Margin % of -5.21%. The current EBITDA Margin % is -5.21%. Viromed Medical AG's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Viromed Medical AG (XTER:VME), the current EBITDA Margin % is -5.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
15GF Score
Get the complete analysis for XTER:VME
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:VME has been successfully added to your 
